ストックスクリーナーアプリを入手
9.57
0.62%
-0.06
プレマーケット:
9.79
0.22
+2.30%
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $15 to $25 - Moomoo
Citigroup Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $16.00 - MarketBeat
ORIC Pharmaceuticals Q1 2026 Financial Report and Forward-Looking Statements - Minichart
MSN Money - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire
ORIC Pharmaceuticals (NASDAQ: ORIC) lifts cash to $419.7M as R&D ramps - Stock Titan
Oric Pharmaceuticals (NASDAQ:ORIC) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ORIC (NASDAQ: ORIC) details Q1 2026 loss and Phase 3 cancer plans - Stock Titan
Cancer drug developer picks Phase 3 dose, has cash into late 2028 - Stock Titan
BRIEF-ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million - TradingView
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates - ChartMill
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Four new ORIC hires receive 216,000 options and 35,000 RSUs - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Shareholders to Reach Out | NDAQ:ORIC | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC ... - Bluefield Daily Telegraph
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent
[ARS] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC Pharmaceuticals (NASDAQ: ORIC) 2026 proxy details equity plan changes, director elections, auditor - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmace - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Investors to Connect - ACCESS Newswire
Oric Pharmaceuticals (ORIC) to Release Earnings on Monday - MarketBeat
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Responsive Playbooks and the ORIC Inflection - Stock Traders Daily
A Look At ORIC Pharmaceuticals (ORIC) Valuation After New Rinzimetostat AACR Prostate Cancer Data - Sahm
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the ... - Caledonian Record
Bronstein, Gewirtz & Grossman, LLC Is Investigating ORIC Pharmaceuticals, Inc. (ORIC) And Encourages Stockholders to Connect - ACCESS Newswire
Oric Pharmaceuticals (ORIC) Stock Housing Data (Grinds Higher) 2026-04-20Retail Flow - Cổng thông tin điện tử Tỉnh Sơn La
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewir - The National Law Review
ORIC Pharmaceuticals, Inc. (ORIC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-04-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ORIC Pharmaceuticals, Inc. (ORIC) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ORIC | Press Release - Stockhouse
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting - Sahm
ORIC Highlights Rinzimetostat's Potential at Cancer Research Mee - GuruFocus
ORIC® Pharmaceuticals Presents Preclinical Data to Support - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceuticals, Inc. (ORIC) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages ORIC Pharmaceutical - The National Law Review
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 105% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
ORIC stock sees biggest intraday slump in over four years – analyst says selloff 'appears exaggerated' - MSN
User - The Chronicle-Journal
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Positive Phase 1b Rinzimetostat Trial Update - Sahm
Why ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial - Sahm
Understanding the Setup: (ORIC) and Scalable Risk - Stock Traders Daily
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation - Moomoo
Oric Pharmaceuticals Stock Rises 6.5%, Analysts Maintain Buy Ratings - National Today
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5%Still a Buy? - MarketBeat
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):